Incyte

Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval

Last week, Eli Lilly and Incyte’s repurposed arthritis treatment baricitinib also scored an EUA in combination with Gilead’s remdesivir for the treatment of hospitalised COVID-19 patients.

Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval

Drug approved for emergency use in combination with Gilead's remdesivir. Eli Lilly and Incyte’s arthritis treatment baricitinib has been repurposed as a COVID-19 treatment, scoring an emergency use

Switzerland: a life sciences hub

American oncology specialist Incyte invested $100m for a monoclonal antibody production site in Yverdon (Vaud).

Incyte launches award programme recognising innovation in GVHD community

have a devastating impact on the lives of patients,” said Barry Flannelly, executive vice president and general manager, US, Incyte. ... Through the Incyte Ingenuity Award, we hope to spark creativity and innovation, which we expect to result in

Incyte’s JAK inhibitor cream clears second eczema trial

Set for regulatory filings later this year. Incyte now has a pair of positive phase 3 trials for its topical formulation of JAK1/2 inhibitor ruxolitinib in atopic dermatitis or eczema, ... Incyte has said it intends to market ruxolitinib cream itself in

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology